Can't find any reference of Regen, but that in itself is fairly interesting, then add the part about Hema heading for trials in Q3 and it looks real good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.